Login to Your Account

Drug/Device Combo Hits Phase III Endpoint

AcelRx Moving Sublingual Analgesic Toward Goal Line

By Marie Powers
Staff Writer

Friday, November 16, 2012
After toiling in the trenches for nearly five years, specialty pharma AcelRx Pharmaceuticals Inc. reported a breakthrough with positive top-line data from the first Phase III study of its lead product candidate, the sublingual Sufentanil NanoTab PCA System (ARX-01), compared to intravenous morphine in postoperative pain.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription